Back to Dashboard







Veradermics, Incorporated (MANE)
Real-time intraday values
Market Overview
From:
To:
MANE Intraday
No data available
SymbolMANE
IPO DateFeb 4, 2026
CEODr. Reid Waldman M.D.
Full Time Employees37
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNYSE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +12.36% | +13.45 US$ |
| 5 Days | +7.75% | +8.79 US$ |
| 1 Month | +14.53% | +15.52 US$ |
| 6 Months | +73.89% | +51.96 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of MANE...
Key Statistics
Market Cap
5.11B
P/E Ratio
N/A
Div Yield
0.00%
52W High
$136.72
52W Low
$32.00
Analyst Consensus
ConsensusStrong Buy
Bullish7100.0%
Neutral00.0%
Bearish00.0%
52W Analyst Price Targets
Min Target
$135.00
$135.00
Max Target
$182.00
$182.00
Current$122.27
Avg Target$164.83
Analyst Recommendations
Target Price:$164.83($135.00 - $182.00)
Community Thoughts
Share your analysis and sentiment on MANE
Join the community to share your analysis
Latest News for MANE

Veradermics’ stock up on male hair loss trial success
Clinical Trials Arena•Oct 19, 2026, 05:18 PM
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment
TIKR•Oct 19, 2026, 05:07 PM

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
MarketBeat•Oct 19, 2026, 05:02 PM
Veradermics stock surges as hair loss drug meets Phase 3 goals
Investing.com•Oct 19, 2026, 01:50 PM
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
BioPharma Dive•Oct 19, 2026, 01:14 PM

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Business Wire•Oct 19, 2026, 11:00 AM

Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Insider Monkey•Sep 12, 2026, 12:29 AM
Veradermics to Present at Upcoming September Investor Conferences
Business Wire•Sep 3, 2026, 09:33 PM

Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Simply Wall St.•Sep 3, 2026, 01:06 AM